Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 3, 2009, Pages 1025-1032

  Funk, Marion ^a   Kriechbaum, Katharina ^a   Prager, Franz ^a   Benesch, Thomas ^b   Georgopoulos, Michael ^a   Zlabinger, Gerhard J ^c   Schmidt Erfurth, Ursula ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR AA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; RETINOPATHY; VISUAL ACUITY; VISUAL IMPAIRMENT; AQUEOUS HUMOR; DRUG ANTAGONISM; INJECTION; METABOLISM; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; BIOLOGICAL MARKERS; CYTOKINES; HUMANS; INJECTIONS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MACULAR EDEMA; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 62649161064     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2510     Document Type: Article

References (27)

1. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140(2)256-261.
2. Patel J, Tombran-Tink J, Hykin P, Gregor T, Cree I. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp Eye Res. 2006;82(5):798-806.
3. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005;243(1):3-8.
4. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye. 2008 Jan;22(1):42-48.
5. Pe'er J, Folberg R, ltin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998;105(3):412-416.
6. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271(2):736-741.
7. Kriechbaum K, Michels S, Prager F, et al. Intravitreal avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2007;92(4):518-522.
8. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-339.
9. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26(3):279-284.
10. Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA. Rebound macular edema following bevacizumab (avastin) therapy for retinal venous occlusive disease. Retina. 2007;27(4):426-431.
11. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611.
12. Feigl B, Graeves A, Brown B. Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity. Clin Ophthalmology. 2007;2:1-9.
13. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487.
14. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120(12):1644-1650.
15. Shih SC, Ju M, Liu N, Smith LE. Selective stimulation of vegfr-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest. 2003;112(1):50-57.
16. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627-1652.
17. Hangai M, Yoshimura N, Yoshida M, Yabuuchi K, Honda Y. Interleukin-1 gene expression in transient retinal ischemia in the rat. Invest Ophthalmol Vis Sci. 1995;36(3):571-578.
18. Jo N, Wu GS, Rao NA. Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2003;44(9):4054-4060.
19. Remick DG. Interleukin-8. Crit Care Med. 2005;33(12 suppl): S466-S467.
20. Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost. 2007;97(5):730-737.
21. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol. 2001;107(2):295-301.
22. Wong DT, Elovic A, Matossian K, et al. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. Blood. 1991;78(10):2702-2707.
23. Cho JY, Miller M, Baek KJ, et al. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest. 2004;113(4):551-560.
24. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ecm proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112(7):1029-1036.
25. Feldman ED, Weinreich DM, Carroll NM, et al. Interferon gammai-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol. 2006;13(1):125-133.
26. Bodnar RJ, Yates CC, Wells A. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res. 2006;98(5):617-625.
27. Boulday G, Haskova Z, Reinders ME, Pal S, Briscoe DM. Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol. 2006;176(5):3098-3107.